Dark Forest Capital Management’s Allogene Therapeutics ALLO Stock Holding History

Dark Forest Capital Management’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,879	Closed	-$15.9K	–	1160
2025 Q1	$15.9K	Buy	+10,879	New	+$20.5K	﹤0.01%	1193
2023 Q1	–	Sell	-39	Closed	-$245	–	1165
2022 Q4	$245	Buy	+39	New	+$361	﹤0.01%	1053
2022 Q1	–	Sell	-383	Closed	-$6K	–	1243
2021 Q4	$6K	Buy	+383	New	+$6.76K	﹤0.01%	1081

Other funds holding ALLO

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Dark Forest Capital Management's ALLO Position: Q2 2025 in Review

Dark Forest Capital Management sold out of Allogene Therapeutics (ALLO) in Q2 2025, closing a stake of 10,879 shares — an estimated $15.9K sold.

Dark Forest Capital Management first reported a position in ALLO in Q4 2021 and held it in 3 quarters. The position peaked at $15.9K in Q1 2025. 158 funds tracked by Wall St. Rank hold ALLO as of Q2 2025.

Dark Forest Capital Management reported no remaining Allogene Therapeutics position as of Q2 2025 after selling out during the quarter.
Dark Forest Capital Management sold 10,879 Allogene Therapeutics shares in Q2 2025, an estimated $15.9K.
Dark Forest Capital Management first reported a position in Allogene Therapeutics in Q4 2021 and held it in 3 quarters.
Dark Forest Capital Management's Allogene Therapeutics position peaked at $15.9K in Q1 2025.
158 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2025.

Based on Dark Forest Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.